Article Text

Download PDFPDF
Ziprasidone monotherapy is ineffective for bipolar-associated anxiety

Statistics from


  • Competing interests BWD has received research support from AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Novartis and Otsuka.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.